<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00220051</url>
  </required_header>
  <id_info>
    <org_study_id>1973</org_study_id>
    <nct_id>NCT00220051</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Oxaliplatin Capecitabine and Pre-operative Radiotherapy for Patients With Locally Advanced and Inoperable Rectal Cancer</brief_title>
  <official_title>A Phase II Study of Oxaliplatin (Eloxatin) Capecitabine (Xeloda) and Pre-operative Radiotherapy for Patients With Locally Advanced and Inoperable Rectal Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy and safety of pre-operative capecitabine and oxaliplatin followed by
      capecitabine with concurrent radiotherapy followed by post-operative capecitabine in the
      treatment of patients with locally advanced or inoperable rectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response rate.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute toxicity has been evaluated in previous phase I studies and should occur to a similar extent.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving pathological down staging compared with the pre-treatment MRI scan</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical complications</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel function and quality of life</measure>
  </secondary_outcome>
  <enrollment type="Actual">109</enrollment>
  <condition>Rectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin, Capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pre operative radiotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical Resection</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18.

          -  Histological diagnosis of adenocarcinoma of rectum.

          -  Locally advanced/ poor prognosis primary rectal cancer defined by MRI criteria of any
             of the categories below;

               -  Tumour within 2 mm of mesorectal fascia ie circumferential resection margin
                  threatened

               -  Any T3 tumour at/below levatores

               -  T3c tumour at any other level ie tumour extends &gt;5 mm into peri-rectal fat

               -  T4 tumour

               -  Any T stage with 4 or more involved lymph nodes

          -  WHO performance status 0, 1 or 2.

          -  No evidence of metastatic disease as determined by CT scan of chest, abdomen, pelvis
             or other investigations such as PET scan or biopsy if required.

          -  Adequate bone marrow function with platelets &gt; 100 X 109/l; WBC &gt; 3 X 109/l;
             neutrophils &gt; 1.5 X 109/l

          -  Normal renal function, with serum creatinine within the normal range or calculated
             creatinine clearance &gt;50 ml/min.

          -  Adequate hepatic function with serum total bilirubin &lt; 1.5 X upper limit of normal
             range.

          -  No concurrent uncontrolled medical conditions

          -  No previous malignant disease other than non-melanotic skin cancer or carcinoma in
             situ of the uterine cervix

          -  Adequate contraceptive precautions if relevant

          -  Informed written consent

        Exclusion Criteria:

          -  Medical or psychiatric conditions that compromise the patient's ability to give
             informed consent

          -  Presence of metastatic disease or recurrent rectal tumour

          -  Renal impairment (creatinine clearance&lt;30 ml/min)

          -  Pregnancy or breast feeding

          -  Patients with a lack of physical integrity of the upper gastrointestinal tract, or
             known malabsorption syndromes

          -  Participation in any investigational drug study within the previous 4 weeks.

          -  Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure,
             symptomatic coronary artery disease and cardiac arrhythmia even if controlled with
             medication) or myocardial infarction within the last 12 months)

          -  Patients with any symptoms or history of peripheral neuropathy.

          -  Prior pelvic radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>D Cunningham</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2005</study_first_submitted>
  <study_first_submitted_qc>September 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>May 30, 2013</last_update_submitted>
  <last_update_submitted_qc>May 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

